Needham & Company Remains Sidelined as Xcerra (XCRA) Reports In-Line 3Q Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
Go back to Needham & Company Remains Sidelined as Xcerra (XCRA) Reports In-Line 3Q Results
June 6, 2016 9:38 AM EDT
Today's Pre-Open Stocks Movers:
ProNAi Therapeutics, Inc. (Nasdaq: DNAI) 55% LOWER; announced disappointing interim results from the Wolverine Phase 2 trial of PNT2258 for the treatment of relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL).
Adamis Pharmaceuticals Corporation (NASDAQ:... More
June 6, 2016 7:07 AM EDT
Xcerra (NASDAQ: XCRA) reported Q3 EPS of $0.00, in-line with the analyst estimate of $0.00. Revenue for the quarter came in at $82.24 million versus the consensus estimate of $81.4 million.
GUIDANCE:
Xcerra sees Q4 2016 EPS of $0.07-$0.10, versus the consensus of $0.09. Xcerra sees... More
June 3, 2016 2:13 PM EDT
The Trading Radar highlights key earnings and economic announcements for the next trading session:
Before Markets Open:
Earnings:
Ability, Inc. (Nasdaq: ABIL) - consensus EPS $0.03
Xcerra (Nasdaq: XCRA) - consensus EPS... More
